AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)
17.59 USD
-0.150 0.846%Sponsored Reports
Loading...
| Previous Close (in USD) | 17.74 |
|---|---|
| Change | -0.150 0.846% |
| 52 W H/L (in USD) | 25.770/3.510 |
| EBITDA (in USD) | -45.852M |
| PE Ratio | -- |
| Volume | 882120 |
| Diluted Eps TTM | -0.46 |
| Total Assets (in USD) | 448.659M |
|---|---|
| Total Liabilities (in USD) | 215.603M |
| Revenue TTM (in USD) | 123.672M |
| Cash (in USD) | 129.883M |
| Market Cap (in USD) | 1,671.527 M |
| Revenue Per Share TTM | 1.489 |
| Gross Profit TTM (in USD) | -10.028M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Employees: 150
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Markus Warmuth M.D. | Pres, CEO & Director | 1971 |
| 2. | Dr. Owen B. Wallace Ph.D. | Chief Scientific Officer | 1969 |
| 3. | Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer | 1975 |
| 4. | Mr. Ajim A. Tamboli C.F.A. | Chief Financial Officer | 1977 |
| 5. | Ms. Jennifer Champoux | Sr. VP of Operations | NA |
| 6. | Dr. Sharon Townson Ph.D. | Chief Technology Officer | 1975 |
| 7. | Mr. Phil Nickson J.D., Ph.D. | Gen. Counsel | 1979 |
| 8. | Dr. John C. Castle Ph.D. | Chief Data Scientist | 1971 |
| 9. | Dr. Jullian G. Jones J.D., M.B.A., Ph.D. | Chief Bus. Officer | 1976 |
| 10. | Dr. Silvia Buonamici Ph.D. | Sr. VP of Drug Discovery Biology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -39.723M | -70.13M | -135.014M | -108.501M | -73.958M |
| Minority Interest | - | - | - | - | - |
| Net Income | -38.626M | -72.7M | -135.352M | -104.618M | -71.942M |
| Selling General Administrative | 36.38M | 35.171M | 32.039M | 27.323M | 15.727M |
| Gross Profit | 115.316M | 67.501M | -6.222M | - | - |
| Reconciled Depreciation | 8.356M | 8.121M | 5.446M | 3.745M | 2.132M |
| Ebit | -54.208M | -81.112M | -143.311M | -112.384M | -72.882M |
| Ebitda | -45.852M | -72.991M | -137.089M | -112.503M | -72.72M |
| Depreciation And Amortization | 8.356M | 8.121M | 6.222M | -0.119M | 0.162M |
| Operating Income | -54.208M | -81.112M | -143.311M | -112.384M | -72.882M |
| Other Operating Expenses | 177.88M | 156.734M | 143.311M | 112.384M | 72.882M |
| Interest Expense | - | - | - | 3.764M | 1.076M |
| Tax Provision | -1.097M | 2.57M | 0.338M | - | - |
| Interest Income | 12.942M | 10.566M | 8.956M | 3.764M | 0.046M |
| Net Interest Income | 12.942M | 10.566M | 8.956M | 3.764M | 0.046M |
| Income Tax Expense | -1.097M | 2.57M | 0.338M | -3.883M | -2.016M |
| Total Revenue | 123.672M | 75.622M | 0M | 0M | 0M |
| Total Operating Expenses | 169.524M | 148.613M | 137.089M | 112.384M | 72.882M |
| Cost Of Revenue | 8.356M | 8.121M | 6.222M | - | - |
| Total Other Income Expense Net | 14.485M | 10.982M | 8.297M | 3.883M | -1.076M |
| Net Income From Continuing Ops | -38.626M | -72.7M | -132.882M | -108.501M | -73.958M |
| Net Income Applicable To Common Shares | - | - | - | -108.501M | -73.958M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 448.659M | 438.732M | 303.755M | 342.389M | 366.329M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 11.481M | 5.118M | 3.294M | 4.444M | 2.595M |
| Total Liab | 215.603M | 215.796M | 124.505M | 70.976M | 18.814M |
| Total Stockholder Equity | 233.056M | 222.936M | 179.25M | 271.413M | 347.515M |
| Other Current Liab | 26.694M | 18.785M | 14.6M | 14.58M | 10.08M |
| Common Stock | 0.007M | 0.006M | 0.005M | 0.005M | 0.005M |
| Capital Stock | 0.007M | 0.006M | 0.005M | 0.005M | 0.005M |
| Retained Earnings | -477.214M | -438.588M | -365.888M | -230.536M | -122.035M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 4.596M | 5.338M |
| Cash | 129.883M | 224.254M | 128.101M | 54.912M | 346.071M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 64.212M | 156.946M | 46.592M | 25.569M | 16.638M |
| Current Deferred Revenue | 29.571M | 117.232M | 17.678M | - | - |
| Net Debt | -90.692M | -181.539M | -82.062M | -7.911M | -346.071M |
| Short Term Debt | 4.397M | 3.714M | 3.162M | 3.127M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 39.191M | 42.715M | 46.039M | 47.001M | - |
| Other Stockholder Equity | 714.09M | 664.874M | 547.857M | 503.696M | 105.237M |
| Property Plant Equipment | - | - | - | 27.075M | 12.325M |
| Total Current Assets | 393.185M | 377.44M | 236.212M | 275.886M | 348.666M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 247.221M | 147.895M | 104.312M | 207.914M | - |
| Net Receivables | 4.6M | 0.173M | 0.505M | 7.656M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | 0.96M | - |
| Accounts Payable | 3.55M | 17.215M | 11.152M | 7.862M | 6.558M |
| Accumulated Other Comprehensive Income | -3.827M | -3.356M | -2.724M | -1.752M | -2.021M |
| Non Currrent Assets Other | 5.102M | 4.978M | 0.352M | 4.596M | 5.338M |
| Non Current Assets Total | 55.474M | 61.292M | 67.543M | 66.503M | 17.663M |
| Capital Lease Obligations | 39.191M | 42.715M | 46.039M | 47.001M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -97.133M | -44.452M | 20.565M | -206.417M | -9.653M |
| Total Cashflows From Investing Activities | -101.833M | -44.452M | 88.801M | -219.219M | -9.653M |
| Total Cash From Financing Activities | 30.351M | 98.892M | 27.492M | 20.466M | 377.562M |
| Net Income | -38.626M | -72.7M | -135.352M | -108.501M | -73.958M |
| Change In Cash | -94.28M | 96.436M | 72.491M | -291.219M | 308.546M |
| Begin Period Cash Flow | 229.117M | 132.681M | 60.19M | 351.409M | 42.863M |
| End Period Cash Flow | 134.837M | 229.117M | 132.681M | 60.19M | 351.409M |
| Total Cash From Operating Activities | -22.798M | 41.996M | -43.802M | -92.466M | -59.363M |
| Depreciation | 8.356M | 8.121M | 6.222M | 3.745M | 2.132M |
| Other Cashflows From Investing Activities | - | - | 0.062M | 0.109M | 0.079M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -0.002M | - | - |
| Sale Purchase Of Stock | -0.357M | -0.641M | -0.116M | 20.83M | 377.562M |
| Other Cashflows From Financing Activities | 30.351M | 98.589M | 27.492M | 0.411M | 139.812M |
| Capital Expenditures | 4.7M | 3.988M | 19.041M | 12.911M | 9.732M |
| Change In Working Capital | -9.189M | 91.397M | 72.466M | -2.134M | 6.286M |
| Other Non Cash Items | -2.204M | -2.948M | -3.807M | 2.76M | 0.96M |
| Free Cash Flow | -27.498M | 38.008M | -62.843M | -105.377M | -69.095M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 2340527 |
| 2. | Avantis US Small Cap Value ETF | 2 months ago | 2296731 |
| 3. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 2057991 |
| 4. | T. Rowe Price Health Sciences | 2 months ago | 1998210 |
| 5. | T. Rowe Price New Horizons | 2 months ago | 1986382 |
| 6. | US Small-Cap Growth II Equity Comp | 5 months ago | 1706251 |
| 7. | iShares Russell 2000 ETF | 2 months ago | 1460940 |
| 8. | HBM Healthcare Investments AG Ord | 5 months ago | 1407040 |
| 9. | T. Rowe Price New Horizons Tr-A | 2 months ago | 900401 |
| 10. | FIAM Small Cap Core Composite | 5 months ago | 746400 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 687905 |
| 12. | FIAM Small Cap Core CIT Cl B | 4 months ago | 646100 |
| 13. | T. Rowe Price Integrated US Sm Gr Eq | 2 months ago | 565639 |
| 14. | T. Rowe Price Integrated US SmCapGrEq | 5 months ago | 536436 |
| 15. | iShares Russell 2000 Value ETF | 2 months ago | 518037 |
| 16. | MEDICAL BioHealth EUR Acc | 3 months ago | 475003 |
| 17. | Fidelity Small Cap Index | 4 months ago | 452316 |
| 18. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 360163 |
| 19. | iShares Biotechnology ETF | 2 months ago | 347150 |
| 20. | Fidelity Extended Market Index | 3 months ago | 321863 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | NEA Management Company, LLC | 5 months ago | 7692298 |
| 2. | T. Rowe Price Associates, Inc. | 8 months ago | 4637060 |
| 3. | TCG Crossover Management, LLC | 5 months ago | 4622151 |
| 4. | Versant Venture Management LLC | 5 months ago | 4382687 |
| 5. | Baker Bros Advisors LP | 5 months ago | 4345736 |
| 6. | Bvf Inc | 5 months ago | 3835886 |
| 7. | BlackRock Inc | 8 months ago | 3815133 |
| 8. | Suvretta Capital Management, LLC | 5 months ago | 3360000 |
| 9. | Vanguard Group Inc | 5 months ago | 3246500 |
| 10. | Aisling Capital Management LP | 5 months ago | 1472331 |
| 11. | Alphabet Inc | 8 months ago | 1464015 |
| 12. | American Century Companies Inc | 5 months ago | 1329619 |
| 13. | FMR Inc | 5 months ago | 1300096 |
| 14. | Geode Capital Management, LLC | 5 months ago | 1204844 |
| 15. | MPM Oncology Impact Management LP | 5 months ago | 1173376 |
| 16. | SILVERARC CAPITAL MANAGEMENT, LLC | 5 months ago | 1029066 |
| 17. | BRAIDWELL LP | 5 months ago | 948316 |
| 18. | State Street Corp | 8 months ago | 846773 |
| 19. | AQR Capital Management LLC | 5 months ago | 785057 |
| 20. | Vestal Point Capital LP | 5 months ago | 775000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...